{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:59:04Z","timestamp":1776448744886,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:54:30Z","timestamp":1773816870000},"page":"285-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy in Men with De Novo Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Ian","family":"Messing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan James","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J Clinicians"},{"issue":"15","key":"10.1016\/j.ucl.2026.02.011_bib2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.canep.2015.04.013","article-title":"A population-based study of progression to metastatic prostate cancer in Australia","volume":"39","author":"Luo","year":"2015","journal-title":"Cancer Epidemiology"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.011_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.annonc.2023.04.515","article-title":"Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer","volume":"34","author":"Sutera","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.011_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2015.02.042","article-title":"Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer","volume":"68","author":"Buzzoni","year":"2015","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.011_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and Follow-Up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.urolonc.2009.09.004","article-title":"Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States","volume":"29","author":"Gilbert","year":"2011","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.011_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433126","article-title":"Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.011_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ucl.2026.02.011_bib20","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-10-0255","article-title":"Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer","volume":"16","author":"Yamaoka","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.ucl.2026.02.011_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.011_bib24","first-page":"1080","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Orthod"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.011_bib25","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.011_bib27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.011_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.ucl.2026.02.011_bib30","first-page":"2974","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.ucl.2026.02.011_bib32","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.011_bib33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ucl.2026.02.011_bib34","first-page":"3595","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Orthod"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","article-title":"Update on the systematic review of palliative radiotherapy trials for bone metastases","volume":"24","author":"Chow","year":"2012","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2023.12.051","article-title":"Clinical outcomes after stereotactic body radiation therapy for nonspinal bone metastases: a systematic review and meta-analysis","volume":"119","author":"Singh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.011_bib37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.08.008","article-title":"Palliative pelvic radiotherapy of symptomatic incurable prostate cancer \u2013 a systematic review","volume":"110","author":"Cameron","year":"2014","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.011_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.radonc.2015.05.021","article-title":"Palliative pelvic radiotherapy for symptomatic incurable prostate cancer \u2013 a prospective multicenter study","volume":"115","author":"Cameron","year":"2015","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib40","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ucl.2026.02.011_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00364","article-title":"The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis","volume":"4","author":"Ganguly","year":"2014","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.011_bib42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","article-title":"Clinical implications of cancer self-seeding","volume":"8","author":"Comen","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.011_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib45","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MOU.0000000000000444","article-title":"Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?","volume":"27","author":"Blanchard","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.011_bib46","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147191","article-title":"Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? Cordes N","volume":"11","author":"Cho","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","article-title":"The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis","volume":"72","author":"L\u00f6ppenberg","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41391-021-00339-y","article-title":"Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer","volume":"24","author":"Morgan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.011_bib50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.011_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","article-title":"STAMPEDE: systemic therapy for advancing or metastatic prostate cancer \u2014 a multi-arm multi-stage randomised controlled trial","volume":"20","author":"James","year":"2008","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ucl.2026.02.011_bib52","author":"James"},{"issue":"10162","key":"10.1016\/j.ucl.2026.02.011_bib53","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"10467","key":"10.1016\/j.ucl.2026.02.011_bib55","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.011_bib56","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.011_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.2156","article-title":"Radiotherapy of the primary tumor and all metastatic lesions in oligometastatic prostate cancer: 5-year results of prolong study","volume":"120","author":"Qi","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2026.02.011_bib58","author":"Hoffman"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","article-title":"Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"86","author":"Roy","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.011_bib60","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.011_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2024.04.011","article-title":"Metastatic hormone-sensitive prostate cancer: patient selection for prostate radiotherapy","volume":"86","author":"Chakrabarti","year":"2024","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009401432600011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009401432600011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:22:03Z","timestamp":1776446523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009401432600011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S009401432600011X"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.011","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy in Men with De Novo Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}